Immuno Oncology Summit
Immuno Oncology Summit
  • Record Attendance
  • Final Agenda Now Available
  • Sponsorship Opportunities
  • Posters

JOIN US NEXT YEAR AT THE PREMIER ANNUAL IO EVENT

AUGUST 28-SEPTEMBER 1, 2017 | SHERATON BOSTON HOTEL

The 2016 Immuno-Oncology Summit brought together 500 scientific leaders from 25 nations, 125 distinguished speakers, and over 20 exhibiting companies across 5 days in Boston to begin a coordinated effort to bring commercial immunotherapies and immunotherapy combinations through clinical development and into the market. This weeklong, nine-meeting set included topics ranging from early discovery through clinical development as well as emerging areas such as oncolytic virotherapy.


 

 

 

Overall, this event provided a focused look at how researchers are applying new science and technology in the development of the next generation of effective and safe immunotherapies and the IO Summit Team is looking forward to 2017! If you have comments or suggestions for next year's program, please contact Samantha Drinkwater at 781-972-5461 or sdrinkwater@healthtech.com.

Who Attended?  

Title

Percent

Executive

26%

Scientist/Technologist

20%

Director

17%

Sales & Marketing

12%

Professor

12%

Manager

11%

Assistant

2%

Company Type

Percent

Biotechnical/Pharma

72%

Financial/Government/Healthcare

14%

Academic

10%

CRO

2%

Other

2%

Conference Tracks

Immunomodulatory Therapeutic Antibodies for CancerOncolytic Virus ImmunotherapyTS: Immunotherapy for Drug DiscoveryRational Combination Cancer ImmunotherapyPersonalized ImmunotherapyPreclinical and Translational Immuno-OncologyAdoptive T Cell TherapyBiomarkers for Immuno-OncologyClinical Trials for Cancer Immunotherapy  

Immunomodulatory Therapeutic Antibodies for CancerOncolytic Virus ImmunotherapyTS: Immunotherapy for Drug DiscoveryRational Combination Cancer ImmunotherapyPersonalized ImmunotherapyPreclinical and Translational Immuno-OncologyAdoptive T Cell TherapyBiomarkers for Immuno-OncologyClinical Trials for Cancer Immunotherapy  

Plenary Keynote Presentations:

Ed_FritschPersonalized, Neoantigen-Based Immunotherapy

Edward Fritsch, Ph.D., Chief Technology Officer, Neon Therapeutics, Inc.

Multiple lines of evidence have demonstrated the critical role that Neoantigens have in the immune response to cancer and the availability of next-generation sequencing to identify personal, neoantigen-creating mutations has opened the door to directly enhance the power and breadth of host immunity to overcome this deadly disease.

Michael RosenzweigEmerging Innate Immune Targets for Enhancing Adaptive Anti-Tumor Responses

Michael Rosenzweig, Ph.D., Executive Director, Biology-Discovery, IMR Early Discovery, Merck Research Laboratories

Novel cancer immunotherapies targeting T cell checkpoint proteins have emerged as powerful tools to induce profound, durable regression and remission of many types of cancer. Despite these advances, multiple studies have demonstrated that not all patients respond to these therapies, and the ability to predict which patients may respond is limited. Harnessing the innate immune system to augment the adaptive anti-tumor response represents an attractive target for therapy, which has the potential to enhance both the percentage and rate of response to checkpoint blockade.

Morganna FreemanReading Tea Leaves: The Dilemma of Prediction and Prognosis in Immunotherapy

Morganna Freeman, D.O., Medical Oncologist, Immunotherapeutics, The Angeles Clinic and Research Institute

With the rapid expansion of immunotherapeutics in oncology, scientifically significant advances have been made with both the depth and duration of antitumor responses. However, not all patients benefit, or quickly relapse, thus much scientific inquiry has been devoted to appropriate patient selection and how such obstacles might be overcome. While more is known about potential biomarkers, accurate prognostication persists as a knowledge gap, and efforts to bridge it will be discussed here.

Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag  


Download Brochure
2016 The Immuno-Oncology Summit Brochure

Corporate Sponsors

Advaxis logo small

Benchling 

Fujifilm Diosynth

HemispheRx

MDBiosciences

Medgenome

Olink Proteomics

Personal Genome Diagnostics

Pieris Pharmaceuticals

Seven Bridges Genomics

Systems Imagination

Transgene


View All Sponsors

View Media Partners

Sponsor & Exhibitor Information

Exhibitor Prospectus

Download 2016 Sponsor and Exhibitor Prospectus